MedTech Terms
    The authoritative reference
    All terms

    AI Act Post-Market Monitoring

    Ongoing, documented monitoring of a high-risk AI system's performance after it is placed on the market.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed July 25, 2026

    Definition

    Article 72 requires providers of high-risk AI systems to establish and document a post-market monitoring system proportionate to the nature of the AI technologies and the risks. The plan must actively and systematically collect, document, and analyse relevant data throughout the lifetime of the system to evaluate continuous compliance.

    What this means in practice

    For MedTech, the AI Act PMM plan should be integrated with the MDR/IVDR post-market surveillance plan and the PMCF/PMPF where required. Drift metrics, calibration checks, and real-world performance thresholds belong in both plans, not as parallel programmes.
    Common pitfalls
    • Running two disconnected post-market programmes for the same device. Regulators expect one integrated view of performance.
    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    EUR-Lex·1FDA·1European Commission·1
    1. 1
      Regulation (EU) 2024/1689, Article 72
      Verified
      EUR-Lexeur-lex.europa.eu
    2. 2
      FDA - Medical Devices
      Verified
      FDAfda.gov
    3. 3
      European Commission - Medical Devices
      Verified
      European Commissionhealth.ec.europa.eu

    Inline markers like [1] jump to the matching reference above.